|Chelsea Therapeutics reports positive Phase III results|
|By Staff and Wire Reports|
|Monday, 20 September 2010 12:09|
Our readers have been in on the secret that is Chelsea Therapeutics since mid-August. The company said that the drug met the main goal of improving the symptoms related to low blood pressure compared to a dummy drug. Northera also showed a statistically significant improvement in standing systolic blood pressure compared to the dummy drug.
Last September, the drug had failed in a late-stage trial as it could not show statistically significant improvement over a dummy drug.
"We are extremely excited by these top-line results which provide validation of the safety and efficacy of Northera as a novel treatment for symptomatic neurogenic orthostatic hypotension, a serious condition for which there is an urgent need for improved treatments," said Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "Symptoms of chronic neurogenic orthostatic hypotension are severe, not only putting patients at high risk for falls and associated injuries but also severely impacting their quality of life and generating significant added health care costs. Northera is the first and only drug to repeatedly demonstrate clinical improvement in these patients by both alleviating symptoms of neurogenic orthostatic hypotension and improving their ability to perform daily activities."